Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cell therapy treats chronic oral disease in cats
Cat dental
Vets used stem cell therapy to cure cats suffering from feline chronic gingivostomatitis. 
Trial offers hope for treatment in humans
 
A novel treatment has been used in the US to treat cats suffering from a painful oral disease.

In a clinical trial, veterinary dental surgeons at the the UC Davis School of Veterinary Medicine used stem cell therapy to cure cats suffering from feline chronic gingivostomatitis (FCGS).

The study is the first of its kind to prove the safety and efficacy of using stem cell therapy for the treatment of the condition.

Vets first became interested in running the trial after seeing several cases where cats had their teeth removed to treat FGCS.

Despite following up the removal with several courses of corticosteroids and antibiotics, the cats still experienced a great deal of pain and suffering.

“FCGS is a challenging disease to treat, and we were frustrated that some cats wouldn’t respond to traditional treatment,” said Boaz Arzi, lead author and veterinary dental surgeon at UC Davis. “We were banging our heads against the wall and this stem cell therapy was a last resort.”

The technique involved taking cat’s own fat-derived stem cells, processing and characterising them. The cells were then given back to the cats intravenously to reduce inflammation and promote tissue regeneration.

Scientists hope that FCGS also has the potential to serve as a useful model for the treatment of oral inflammatory disease in humans. Nasim Fazel, a dentist at the UC Davis Health system has been working with the veterinary team to perform comparative studies.

“I was really excited to hear about their work because the cat disease behaved very similarly to what i saw in my human patients, said Fazel.

Based in the success of this research, she recently submitted a grant to establish a human clinical trial to treat oral lichen plans - a similar chronic inflammatory disease in humans.

“We’re in desperate need of novel therapies to treat chronic inflammatory mucosal disorders such as OLP, which are challenging to treat and of major impact to patients’ quality of life,” Fazel said.

“Having this opportunity to translate what we’re learning in veterinary medicine to human medicine and working together to bring therapies discovered in the cat model to chronic oral inflammatory diseases in humans is exciting and has great potential.”

Results of the trial recently appeared the journal Stem Cells Translational Medicine

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.